Arcus Biosciences Inc (NYSE: RCUS) – Suitable For Long Term Buy?
Currently, there are 75.50M common shares owned by the public and among those 48.50M shares have been available to trade. The company’s stock has a 5-day price change of -4.94% and 13.60% over the past three months. RCUS shares are trading -10.37% year to date (YTD), with the 12-month market performance down to -14.78% lower. […]
Look At Analyst Expectations For A Better Read On Arcus Biosciences Inc (NYSE: RCUS)
BlackRock Fund Advisors recently announced the acquisition of new stake in Arcus Biosciences Inc (NYSE:RCUS). The institutional investor has increased its shareholding in the Healthcare company by 0.08% to 8.34 million shares with purchase of 6884.0 shares. This fresh investment now brings its stake to 11.14% valued currently at $159.27 million. In addition, Fidelity Management […]
